| abstract |
This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted amino-azepines, according to Formula I n nSpecifically, the invention is directed to compounds according to Formula I n nwherein: n nR1 is optionally substituted C 3-7 cycloalkyl, optionally substituted C 3-7 cycloalkenyl, optionally substituted Het-C 3-7 alkyl, optionally substituted Het-C 3-7 alkenyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, or optionally substituted indenyl; n nR2 is H, optionally substituted C 1-6 alkyl, C 3-6 cycloalkyl-C 0-6 alkyl, Ar—C 0-6 alkyl, or Het-C 0-6 alkyl; n neach R3 is independently H, optionally substituted C 1-8 alkyl, optionally substituted C 2-8 alkenyl, optionally substituted C 2-8 alkynyl, Het-C 1-6 alkyl, optionally substituted C 3-6 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, or optionally substituted C 1 -C 6 alkoxy; n nR4 is H, or optionally substituted C 1 -C 4 alkyl; n nR5 is H, optionally substituted C 1-8 alkyl, optionally substituted C 2-8 alkenyl, optionally substituted C 2-8 alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; n nR6 is H or C 1-6 alkyl; and n nX is SO 2 , CO, CH 2 , or CONH, nand pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. |